Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 5/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | BMP1 | P13497 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3339558 | 0.72 | SLC2A1 (0.42) | SLC2A1BACE1TP53GPR119LMNA | |
| SCHEMBL4155287 | 0.68 | ALDH1A1 (0.59) | SLC2A1BACE1TP53GPR119LMNA | |
| SCHEMBL20015307 | 0.68 | ALDH1A1 (0.61) | BACE1TP53GPR119LMNAALDH1A1 | |
| SCHEMBL562970 | 0.68 | SLC2A1 (0.43) | SLC2A1BACE1TP53LMNAALDH1A1 | |
| SCHEMBL28169019 | 0.67 | ALDH1A1 (0.62) | BACE1TP53GPR119LMNAALDH1A1 | |
| SCHEMBL562610 | 0.66 | SLC2A1 (0.42) | SLC2A1BACE1TP53LMNAALDH1A1 | |
| SCHEMBL19123612 | 0.65 | ALDH1A1 (0.51) | SLC2A1BACE1TP53GPR119LMNA | |
| SCHEMBL6011511 | 0.64 | STS (0.56) | BACE1TP53GPR119LMNAALDH1A1 | |
| SCHEMBL18669506 | 0.63 | STS (0.55) | SLC2A1BACE1TP53GPR119LMNA | |
| SCHEMBL30954953 | 0.63 | GPR119 (0.52) | TP53GPR119ALDH1A1BMP1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | IL2, IL4, IL4I1 | SLC2A1 4808/4885BACE1 4765/4885TP53 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.